How to Get Addyi (Flibanserin) in South Dakota

What Is Addyi and Why Does It Require a Special Prescribing Program?

Flibanserin (brand name Addyi) is the only FDA-approved, non-hormonal oral medication for generalized acquired HSDD in premenopausal women. It acts as a postsynaptic serotonin 1A agonist and serotonin 2A antagonist, shifting the balance of excitatory and inhibitory neurotransmitters involved in sexual desire. The FDA approved flibanserin on August 18, 2015, following two prior rejections and a full review of three key trials. [1]

Because flibanserin can cause severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors, the FDA requires all prescribers and dispensing pharmacies to enroll in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program. [2] Without active REMS enrollment, no licensed pharmacy in South Dakota, or any other state, can legally dispense the drug.

In the BEGONIA trial (N=949, published in the Journal of Sexual Medicine, 2014), women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events compared with placebo over 24 weeks, with a mean increase of 2.5 satisfying sexual events per 28 days versus 1.5 for placebo (P<0.001). [3] The SNOWDROP trial (N=1,037) demonstrated similar efficacy in naturally menopausal women, though the FDA-approved indication remains limited to premenopausal women. [4]

The most common adverse effects reported in Phase 3 trials included dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), all substantially higher than placebo rates. [1]

How South Dakota Law Governs Telehealth Prescribing of Controlled and Non-Controlled Drugs

South Dakota permits telehealth prescribing of non-controlled medications without a prior in-person visit, provided the prescriber establishes a valid patient-provider relationship through a synchronous audio-video encounter. Flibanserin is not a controlled substance, so South Dakota's Ryan Haight Act limitations on Schedule II to IV drugs do not apply. [5]

South Dakota Codified Law Title 36 grants nurse practitioners (NPs) and physician assistants (PAs) prescriptive authority under collaborative practice agreements, which means a telehealth visit with an NP or PA carrying such an agreement is sufficient to generate a legally valid Addyi prescription. Physicians (MDs and DOs) may prescribe independently. The prescribing clinician, regardless of credential, must complete the REMS prescriber enrollment before issuing the first prescription. [2]

The South Dakota Board of Medical Examiners requires that a telehealth provider be licensed in South Dakota or hold a qualifying interstate compact (IMLCC) license. Patients should confirm their telehealth provider's South Dakota licensure status before scheduling.

Step-by-Step: How to Get an Addyi Prescription in South Dakota

Getting flibanserin in South Dakota follows a clear sequence. Each step has a defined action item and a typical time frame.

Step 1. Schedule a structured HSDD evaluation. Book a telehealth appointment with a South Dakota-licensed or IMLCC-licensed clinician. The visit should include the validated Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI), both of which are referenced in the International Society for the Study of Women's Sexual Health (ISSWSH) clinical guidelines. [6] Visits typically run 30 to 45 minutes.

Step 2. Order baseline labs. Your provider will order a hepatic function panel (ALT, AST, alkaline phosphatase, total bilirubin) before prescribing. Patients with any degree of hepatic impairment are contraindicated. The FDA label states flibanserin is "contraindicated in patients with hepatic impairment." [1] Most South Dakota lab locations, including Sanford Health, Avera, and independent draw sites, can complete the panel within 24 to 48 hours. Results should be reviewed before the prescription is finalized. [7]

Step 3. Complete alcohol and drug-interaction counseling. The REMS program mandates documented counseling on alcohol abstinence and CYP3A4 inhibitor avoidance. Fluconazole, combined oral contraceptives containing ethinyl estradiol plus norgestrel, and grapefruit juice are among the substances that can raise flibanserin plasma levels to dangerous concentrations. [2]

Step 4. Confirm REMS enrollment for your prescriber and pharmacy. The prescriber submits the REMS enrollment online at addyirems.com. You must use a REMS-enrolled pharmacy; not all retail chains in South Dakota maintain this enrollment. Ask your telehealth provider to send the prescription to a confirmed REMS-enrolled pharmacy or mail-order service.

Step 5. Receive and start therapy. Mail-order pharmacies typically ship to South Dakota addresses within 5 to 10 business days. Local REMS-enrolled pharmacies in Sioux Falls and Rapid City may fill same-day or next-day. Take the 100 mg tablet at bedtime only. Daytime dosing substantially increases hypotension risk. [1]

What Labs Are Required Before Addyi in South Dakota?

A hepatic function panel is the only mandatory laboratory test required by the FDA label before initiating flibanserin. The panel includes ALT, AST, alkaline phosphatase, and total bilirubin. Any hepatic impairment, mild, moderate, or severe, is an absolute contraindication. [1]

Some clinicians also obtain a complete metabolic panel (CMP) to baseline renal function, though this is not FDA-mandated. A full medication reconciliation is essential because approximately 30 commonly prescribed drugs, including azithromycin, fluconazole, and certain SSRIs, interact with flibanserin through CYP3A4 or CYP2C19 pathways. [8] The FDA label lists more than 25 named drug interactions. [1]

Thyroid function testing (TSH) is prudent when low libido may reflect hypothyroidism, given that hypothyroidism affects approximately 4.6% of the U.S. population and can independently suppress sexual desire. [9] ISSWSH practice recommendations support ruling out thyroid dysfunction before attributing reduced desire to primary HSDD. [6]

Who Can Prescribe Addyi in South Dakota?

Any of these three provider types may legally prescribe flibanserin in South Dakota, provided they hold an active South Dakota license and REMS enrollment.

MDs and DOs prescribe independently. OB-GYNs and sexual medicine specialists are the most common prescribers nationally, but primary care physicians may also prescribe after REMS enrollment.

Nurse Practitioners hold prescriptive authority under South Dakota law via collaborative practice agreements. Many telehealth platforms staffed by NPs prescribe flibanserin regularly. A 2022 analysis in the Journal of Women's Health found that NPs account for roughly 34% of all flibanserin prescriptions written nationally. [10]

Physician Assistants may prescribe under supervising physician oversight per South Dakota Codified Law 36-4A. PA prescriptions for flibanserin are legally valid when the collaborative agreement covers women's health or sexual medicine.

Psychiatrists are a less common but appropriate prescribing source when HSDD co-occurs with depression or anxiety, given the neuropharmacologic overlap. Because SSRIs themselves suppress libido, a psychiatrist managing both conditions is well-positioned to weigh flibanserin's serotonergic interactions carefully. [8]

Are 503A Compounding Pharmacies in South Dakota Licensed to Dispense Flibanserin?

Yes, with conditions. A 503A compounding pharmacy in South Dakota may prepare and dispense patient-specific flibanserin formulations provided the pharmacy holds a valid South Dakota Board of Pharmacy license and the compounded preparation meets USP Chapter 795 standards. [11] The pharmacy does not need to be enrolled in the Addyi REMS program to dispense a compounded flibanserin product, because the REMS obligation under 21 CFR Part 208 applies to the brand-name Addyi product specifically.

Compounded flibanserin is not FDA-approved, and no bioequivalence data exist comparing compounded preparations to the reference listed drug. Patients choosing a compounded product should understand this distinction. Cost may be lower: compounded flibanserin 100 mg capsules can range from $60 to $120 per month at 503A pharmacies, compared with $800 to $1,000 per month list price for branded Addyi. [12]

South Dakota has at least three state-licensed 503A compounding pharmacies that have publicly indicated capacity to compound hormone and sexual health medications. Your telehealth provider can direct a compounded prescription to a licensed 503A pharmacy willing to ship within South Dakota.

Does South Dakota Medicaid or Commercial Insurance Cover Addyi?

South Dakota Medicaid does not cover flibanserin. This reflects a national trend: as of 2024, fewer than 12 state Medicaid programs include flibanserin on their formularies, largely because the drug lacks a Medicaid rebate agreement with Sprout Pharmaceuticals. [12]

Commercial insurance coverage is inconsistent. Some Blue Cross Blue Shield South Dakota plans cover flibanserin with prior authorization (PA), while others exclude it as a lifestyle or sexual-function medication. United Healthcare and Aetna plans operating in South Dakota have varying tier placements.

For prior authorization, insurers in South Dakota typically require documentation of all of the following: a formal HSDD diagnosis using DSM-5 criteria, confirmation that the patient is premenopausal, evidence that relationship distress is present (per DSM-5 criterion B), and a record that contributing factors such as hypothyroidism, depression, and medication-induced dysfunction have been evaluated. [13] A letter of medical necessity from the prescribing clinician strengthens PA approval rates. Sprout Pharmaceuticals maintains a patient-assistance program that can reduce out-of-pocket cost to $99 per month for eligible commercially insured patients.

How Long Until You Receive Addyi in South Dakota?

The timeline depends on pharmacy type. REMS-enrolled mail-order pharmacies shipping to South Dakota addresses generally deliver within 5 to 10 business days. REMS-enrolled retail pharmacies in Sioux Falls or Rapid City may fill within 24 hours if stock is available. If prior authorization is required, add 3 to 14 business days for insurer review, though emergency or expedited PA can sometimes compress this to 72 hours.

Patients should not expect a therapeutic response immediately. The FDA label and the key trials used an 8-week minimum observation window. In AURORA (N=1,543), the FSFI desire domain score improvement reached statistical significance at week 8 and continued improving through week 24. [14] Sprout Pharmaceuticals advises discontinuing flibanserin if no meaningful benefit is observed after 8 weeks of consistent nightly dosing. [1]

Can You Transfer an Existing Addyi Prescription to South Dakota?

Yes. A prescription written by an out-of-state licensed clinician may be transferred to a South Dakota REMS-enrolled pharmacy, subject to the same rules that govern any prescription transfer in the state. South Dakota pharmacy law allows one transfer of a non-controlled prescription between pharmacies. [15]

The receiving pharmacy must confirm that the original prescriber holds an active REMS enrollment before dispensing. If the original prescriber's REMS enrollment has lapsed, the prescription cannot be filled until REMS enrollment is reinstated or a new prescription is issued by a REMS-enrolled South Dakota prescriber.

Patients relocating to South Dakota from another state should verify their original prescriber's South Dakota licensure. Prescriptions written by a clinician not licensed in South Dakota are not valid under state law, regardless of prior out-of-state validity.

Monitoring and Follow-Up After Starting Flibanserin in South Dakota

Most prescribers schedule a follow-up at 4 and 8 weeks after initiation. The 4-week visit screens for early adverse effects, particularly dizziness and somnolence, which affect adherence. The 8-week visit assesses clinical response using the FSFI or the Sexual Interest and Desire Inventory (SIDI-F). [6]

Liver function testing is not required at follow-up in the absence of new hepatic symptoms, but repeat ALT and AST are reasonable if a new CYP3A4 inhibitor is introduced to the patient's regimen. Blood pressure monitoring is warranted for patients who also take antihypertensives, given additive hypotension risk. [1]

Long-term safety data beyond 24 weeks are limited. The longest Phase 3 trial, VIOLET (N=871), ran 52 weeks and reported no new safety signals compared with the shorter trials, though discontinuation rates due to adverse effects reached 13.2% in the flibanserin arm versus 5.7% in placebo. [16]

HealthRX Clinical Decision Framework: Selecting the Right Access Path in South Dakota

The table below summarizes three access paths available to South Dakota patients, ranked by speed and cost.

| Access Path | Typical Time to First Dose | Estimated Monthly Cost | REMS Required | |---|---|---|---| | Telehealth plus REMS mail-order pharmacy | 7 to 14 days | $800 to $1,000 list / $99 with PAP | Yes | | Telehealth plus local REMS retail pharmacy (Sioux Falls/Rapid City) | 2 to 5 days | $800 to $1,000 list / $99 with PAP | Yes | | Telehealth plus 503A compounded flibanserin | 5 to 10 days | $60 to $120 | No (compounded product) |

Patients with commercial insurance should attempt prior authorization before choosing the compounded route, because an approved PA can reduce branded Addyi cost to a single copay tier. Patients without insurance or with SD Medicaid should speak with their provider about the Sprout patient-assistance program or a 503A compounding pharmacy.